Skip to main content

Table 1 Interaction analyses for individual KIR and KIR ligand genotypes with TTRF

From: Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

   

TTRF

Line

Treatment

Genotype Group

Number of Events/n

4 yr Fail Rate (95% CI)a %

Interaction p-value

1

Maintenance

KIR2DL1+/C2+

21/52

38 (25–54)

0.524

2

Maintenance

not KIR2DL1+/C2+

7/28

30 (15–56)

3

Non-Maintenance

KIR2DL1+/C2+

18/49

38 (26–55)

4

Non-Maintenance

not KIR2DL1+/C2+

6/30

21 (9–43)

5

Maintenance

KIR2DL2+/C1+

11/36

32 (18–53)

0.547

6

Maintenance

not KIR2DL2+/C1+

17/44

38 (25–56)

7

Non-Maintenance

KIR2DL2+/C1+

6/28

24 (10–49)

8

Non-Maintenance

not KIR2DL2+/C1+

18/51

36 (24–52)

9

Maintenance

KIR2DL3+/C2+

17/56

33 (21–50)

0.982

10

Maintenance

not KIR2DL3+/C2+

11/24

41 (23–64)

11

Non-Maintenance

KIR2DL3+/C2+

16/60

27 (17–43)

12

Non-Maintenance

not KIR2DL3+/C2+

8/19

45 (25–70)

13

Maintenance

KIR3DL1+/Bw4+

20/54

38 (25–55)

0.055

14

Maintenance

not KIR3DL1+/Bw4+

8/26

29 (15–52)

15

Non-Maintenance

KIR3DL1+/Bw4+

13/50

25 (15–41)

16

Non-Maintenance

not KIR3DL1+/Bw4+

11/29

43 (25–66)

  1. a95% Confidence interval; lines 13-14 (bolded text) had a p-value <0.100 and were analyzed further for associations with outcome
Back to article page